RDS | Rheumatologic Dermatology Society



Rheumatologic Dermatology Society (RDS) Annual MeetingSaturday, November 7, 2015 8am to 5pmMission Bay Conference Center at UCSFFisher Banquet Room West 1675 Owens Street, Suite 251 San Francisco, CAAGENDA8-8:30Continental breakfast (Fisher Banquet Room East)8:30-8:45WelcomeDavid Fiorentino (Stanford University)8:45-9:30Update on the cutaneous lupus classification projectJoe Merola (Brigham and Women’s Hospital)9:30-10The Vasculitis Clinical Research ConsortiumPeter Merkel and Rob Micheletti (University of Pennsylvania)10-10:15BreakNovel targets for therapy in dermatomyositis10:15-10:45IntroductionJan Dutz (University of British Columbia)10:45-11:15Interferons in dermatomyositisSteve Greenberg (Brigham and Women’s Hospital)11:15-11:30Activity of type I and type II interferons in dermatomyositis skin is correlated with characteristic pathologic featuresHayley Leatham, Kerri Rieger, Lorinda Chung, Shufeng Li, Brandon Higgs, Yihong Yao, Kavita Sarin, David FiorentinoStanford University, Department of Dermatology11:30-11:45The Janus kinase inhibitor tofacitinib is an alternative treatment option for refractory cutaneous dermatomyositisDrew Kurtzman, Natalie Wright, Janice Lin, Alisa Femia, Henry Townsend, Mital Patel, Ruth Ann VleugelsBrigham and Women’s Hospital, Department of Dermatology12-1Lunch (Fisher Banquet Room East)Cutaneous Lupus Erythematosus1-1:15Activation of T-Follicular Helper Cells and B Cells in Ultraviolet Light-Induced Murine Model of Systemic Lupus ErythematosusMisha Zarbafian, Mehran Ghoreishi, Jan DutzUniversity of British Columbia, Department of Dermatology1:15-1:30Immunohistochemical characterization of acute and chronic discoid lupus erythematosus skin lesionsJack C. O’Brien, Gregory A. Hosler, Benjamin F. Chong, MDUniversity of Texas, Southwestern, Department of Dermatology1:30-1:45Belimumab for the treatment of recalcitrant cutaneous lupus – a pilot projectPriyanka Vashisht, Manpreet Sethi, Melanie Rohr, Debbie Lim, Michelene Hearth-HolmesUniversity of Nebraska Medical Center, Division of RheumatologyParaneoplastic skin disease1:45-2Myelodysplastic syndrome presenting as generalizedgranulomatous dermatitisSamuel J. Balin, David A. Wetter, Paul J. Kurtin, Louis Letendre, Mark R. PittelkowMayo Clinic, Department of Dermatology2-2:15Evidence-Based Malignancy Screening in patients with DermatomyositisAnthony P. Fernandez, Fabrizio Galimberti, Yumeng LiCleveland Clinic, Department of Dermatology2:15-2:30Outcomes of malignancy screening practices for dermatomyositis: data from two U.S. cohortsHayley Wheeler, Courtney Schadt, Sarah Chisolm, Deborah Fretwell, Lorinda Chung, Jeffrey Callen, David FiorentinoStanford University, Department of DermatologyUniversity of Louisville, Division of DermatologyMorphea2:30-2:45Changes of disease activity and damage over time in morphea PatientsJack C. O’Brien and Heidi T. JacobeUniversity of Texas, Southwestern, Department of Dermatology2:45-3Epidemiology and treatment of post-irradiation morphea: a retrospective analysis from three large tertiary care centersRenee Fruchter, Drew Kurtzman, Daniel R. Mazori, Natalie A. Wright, Mital Patel, Ruth Ann Vleugels, Alisa N. FemiaBrigham and Women’s Hospital, Department of DermatologyNew York University, Department of Dermatology3-3:15BreakInstruments for skin assessment in dermatomyositis3:15-3:30Evaluation of the Reliability and Validity of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and the Cutaneous Assessment Tool-Binary Method (CAT-BM) Among Pediatric Dermatologists, Rheumatologists, and Neurologists in Juvenile DermatomyositisJanice Tiao, Neelam Khan, Rui Feng, Emily M. Berger, John Brandsema, Carrie C. Coughlin, Elizabeth A. Kichula, Melissa A. Lerman, Svetlana Lvovich, Patrick J. McMahon, Lisa G. Rider, Adam I. Rubin, Lisabeth V. Scalzi, Douglas M. Smith, Alysha J. Taxter, James R. Treat, Sabrina W. Yum, Joyce Okawa, Victoria P. WerthUniversity of Pennsylvania, Department of Dermatology3:30-3:45The Cutaneous Dermatomyositis Disease Area and Severity Index as a primary efficacy endpoint in a Phase 2 clinical trial of IMO-8400 in patients with dermatomyositisDavid Fiorentino, Mark Hurtt, Julie Brevard, Victoria WerthStanford University, Department of DermatologyIDERA Pharmaceuticals, Inc.University of Pennsylvania, Department of DermatologyMisc3:45-4Good Syndrome - An adult onset immunodeficiency associated with autoimmunityJan DutzUniversity of British Columbia, Department of Dermatology4-4:30Website update4:30-5RDS business meetingNominations and membership: Nicole Fett (Oregon Health Sci U)Amendments to bylaws: David Fiorentino (Stanford)Other business ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download